Latest period
$19.7B
YoY change
-0.1%
5Y CAGR
+1.2%
Peak year (FY2022)
$24.2B
Latest annual
$17.8B
Free Cash Flow history chart for AbbVie (ABBV) from 2016 to 2025
Latest: $17.8B
Free Cash Flow growth chart for AbbVie (ABBV) from 2016 to 2025
Latest: -0.1%
Free Cash Flow history table for AbbVie (ABBV) from 2009 to 2025
| FY2025 | $17.8B | -0.1% | -$16M | ||
| FY2024 | $17.8B | -19.2% | -$4.23B | ||
| FY2023 | $22.1B | -9.0% | -$2.19B | ||
| FY2022 | $24.2B | +10.3% | +$2.26B | ||
| FY2021 | $22B | +31.0% | +$5.2B | ||
| FY2020 | $16.8B | +31.5% | +$4.02B | ||
| FY2019 | $12.8B | -0.1% | -$17M | ||
| FY2018 | $12.8B | +35.6% | +$3.36B | ||
| FY2017 | $9.43B | +43.7% | +$2.87B | ||
| FY2016 | $6.56B | -6.3% | -$441M | ||
| FY2015 | $7B | +138.4% | +$4.07B | ||
| FY2014 | $2.94B | -49.2% | -$2.84B | ||
| FY2013 | $5.78B | -3.9% | -$236M | ||
| FY2012 | $6.01B | +2.0% | +$121M | ||
| FY2011 | $5.89B | +30.1% | +$1.36B | ||
| FY2010 | $4.53B | -10.4% | -$527M | ||
| FY2009 | $5.05B | — | — |
- FY2025$17.8B-0.1%
- FY2024$17.8B-19.2%
- FY2023$22.1B-9.0%
- FY2022$24.2B+10.3%
- FY2021$22B+31.0%
- FY2020$16.8B+31.5%
- FY2019$12.8B-0.1%
- FY2018$12.8B+35.6%
- FY2017$9.43B+43.7%
- FY2016$6.56B-6.3%
- FY2015$7B+138.4%
- FY2014$2.94B-49.2%
- FY2013$5.78B-3.9%
- FY2012$6.01B+2.0%
- FY2011$5.89B+30.1%
- FY2010$4.53B-10.4%
- FY2009$5.05B—
Free Cash Flow values are taken from AbbVie's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Free Cash Flow at AbbVie (ABBV)
Free Cash Flow for AbbVie (ABBV): headline value $19.7B · YoY -0.1%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
The 2025 reading of AbbVie (ABBV) free cash flow is $17.8B – edged down 0.1% year-over-year.
Over 2020–2025 (5 years), AbbVie free cash flow expanded at a +1.2% compound annual rate, with mixed annual results across the window.
AbbVie free cash flow peaked at $24.2B in 2022; the latest annual figure is $17.8B in 2025 (26.5% below peak).
The record annual free cash flow stands at $24.2B, reached in 2022; the historical low of $2.94B was recorded in 2014.
AbbVie Free Cash Flow by Year
AbbVie Free Cash Flow 2025: $17.8B
In 2025, AbbVie reported free cash flow of $17.8B, edged down 0.1% below 2024.
AbbVie Free Cash Flow 2024: $17.8B
AbbVie free cash flow in 2024 was $17.8B, declined 19.2% below 2023.
AbbVie Free Cash Flow 2023: $22.1B
2023's free cash flow for AbbVie came in at $22.1B, declined 9.0% below 2022.
AbbVie Free Cash Flow 2022: $24.2B
AbbVie posted free cash flow of $24.2B in 2022, grew 10.3% from 2021. This figure represents the highest annual value in the available history.
AbbVie Free Cash Flow 2021: $22B
AbbVie free cash flow in 2021 was $22B.
See more financial history for AbbVie (ABBV).
Sector peers by Free Cash Flow
Healthcare peers of AbbVie (ABBV), ranked by their latest free cash flow
| $19.7B | |
| $16.1B | |
| $12.4B | |
| $8.97B | |
| $8.67B | |
| $8.1B | |
| $6.29B | |
| $4.52B |
- $19.7B
- $16.1B
- $12.4B
- $8.97B
- $8.67B
- $8.1B
- $4.52B
Frequently asked questions
AbbVie (ABBV) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
How this company returns cash to shareholders — buybacks, dividends, and stock splits.